News & Events
IFM CAB Member Michael Heneka Discusses Alzheimer’s Study in Alzforum
A study recently published in Nature by IFM Therapeutics scientific co-founder Dr. Eicke Latz and clinical advisory board member Dr. Michael Heneka demonstrated inflammation-driven, NLRP3-associated pathways may represent a novel therapeutic target for Alzheimer’s.
Dr. Heneka was interviewed about the research and therapeutic implications for future Alzheimer’s treatments in Alzforum, a news site dedicated to advancing the development of diagnostics and treatments for Alzheimer’s disease and related disorders. View the full story, “Do Microglia Spread Aβ Plaques?”, on Alzforum.